How to take Erdafitinib
Doctors will choose Erdafitinib (Erdafitinib) to treat patients with locally advanced or metastatic bladder urothelial cancer based on the presence of susceptible FGFR gene alterations in tumor specimens detected by FDA-approved companion diagnostics. The recommended dose of erdafitinib is 8 mg orally once daily (two 4 mg tablets), with the dose increased to 9 mg (three 3 mg tablets) once daily on days 14 to 21 based on serum phosphate (PO4) levels and tolerability. Treatment should be continued until disease progression or unacceptable toxicity occurs.
Dose escalation based on serum phosphate levels, patients assessed serum phosphate levels 14 to 21 days after initiating treatment. If serum phosphate levels are <5.5 mg/dL and there are no eye disorders or grade 2 or higher adverse reactions, increase the dose of erdafitinib to 9 mg once daily and monitor phosphate levels monthly for hyperphosphatemia. If a patient develops adverse reactions after taking erdafitinib, the doctor will adjust the dose according to the severity of the adverse reaction, taking the dose of 8 mg orally once daily The first dose of patients with 8 mg is reduced to 6 mg (two 3 mg tablets), the second dose is reduced to 5 mg (one 5 mg tablet), and the third dose is reduced to 4 mg (one 4 mg tablet). Patients who cannot tolerate the once daily oral dose of 4 mg should stop Erdatinib treatment.
The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)